BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
0.575
-0.013 (-2.19%)
Nov 21, 2024, 2:18 PM EST - Market open
BioXcel Therapeutics Stock Forecast
BTAI's stock price has decreased by -85.17% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for BTAI stock have an average target of 5.00, with a low estimate of 1.00 and a high estimate of 7.00. The average target predicts an increase of 769.41% from the current stock price of 0.58.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 21, 2024.
Analyst Ratings
The average analyst rating for BTAI stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 5 | 5 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $5 | Strong Buy | Maintains | $7 → $5 | +769.41% | Oct 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +1,117.18% | Sep 6, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $7 | Strong Buy | Maintains | $7 | +1,117.18% | Aug 30, 2024 |
| UBS | UBS | Hold Maintains $3.5 → $1 | Hold | Maintains | $3.5 → $1 | +73.88% | Aug 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $7 | Strong Buy | Maintains | $10 → $7 | +1,117.18% | Aug 8, 2024 |
Financial Forecast
Revenue This Year
4.79M
from 1.38M
Increased by 247.03%
Revenue Next Year
9.01M
from 4.79M
Increased by 88.16%
EPS This Year
-2.07
from -6.15
EPS Next Year
-1.70
from -2.07
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 5.6M | 11.4M | 26.3M | ||
| Avg | 4.8M | 9.0M | 21.7M | ||
| Low | 4.0M | 5.8M | 13.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 308.6% | 138.3% | 191.3% | ||
| Avg | 247.0% | 88.2% | 141.2% | ||
| Low | 192.7% | 20.8% | 52.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.75 | -1.05 | -0.66 | ||
| Avg | -2.07 | -1.70 | -1.32 | ||
| Low | -2.34 | -2.68 | -2.50 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.